- Home
- IOVA vs KZR Comparison
IOVA vs KZR Comparison
Compare IOVA & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- KZR
- Stock Information
- Founded
- IOVA 2007
- KZR 2015
- Country
- IOVA United States
- KZR United States
- Employees
- IOVA N/A
- KZR N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- IOVA Health Care
- KZR Health Care
- Exchange
- IOVA Nasdaq
- KZR Nasdaq
- Market Cap
- IOVA 771.4M
- KZR N/A
- IPO Year
- IOVA N/A
- KZR 2018
- Fundamental
- Price
- IOVA $1.88
- KZR $4.52
- Analyst Decision
- IOVA Buy
- KZR Hold
- Analyst Count
- IOVA 10
- KZR 2
- Target Price
- IOVA $12.22
- KZR $9.00
- AVG Volume (30 Days)
- IOVA 10.4M
- KZR 42.6K
- Earning Date
- IOVA 08-07-2025
- KZR 08-12-2025
- Dividend Yield
- IOVA N/A
- KZR N/A
- EPS Growth
- IOVA N/A
- KZR N/A
- EPS
- IOVA N/A
- KZR N/A
- Revenue
- IOVA $212,679,000.00
- KZR N/A
- Revenue This Year
- IOVA $86.62
- KZR N/A
- Revenue Next Year
- IOVA $69.95
- KZR N/A
- P/E Ratio
- IOVA N/A
- KZR N/A
- Revenue Growth
- IOVA 11070.12
- KZR N/A
- 52 Week Low
- IOVA $1.64
- KZR $3.62
- 52 Week High
- IOVA $12.51
- KZR $9.18
- Technical
- Relative Strength Index (RSI)
- IOVA 47.47
- KZR 51.73
- Support Level
- IOVA $1.68
- KZR $4.45
- Resistance Level
- IOVA $2.02
- KZR $4.81
- Average True Range (ATR)
- IOVA 0.11
- KZR 0.29
- MACD
- IOVA 0.03
- KZR 0.02
- Stochastic Oscillator
- IOVA 61.42
- KZR 60.81
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.